| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 03/07/2002 | CA2420696A1 Isolated human drug-metabolizing proteins, nucleic acid molecules and uses thereof |
| 03/07/2002 | CA2420659A1 Genes expressed in the cell cycle |
| 03/07/2002 | CA2420363A1 Pyrazole derivatives and their use as protein kinase inhibitors |
| 03/07/2002 | CA2420062A1 Erbb4 antagonists |
| 03/07/2002 | CA2419699A1 Gem-substituted .alpha. v .beta. 3 integrin antagonists |
| 03/06/2002 | EP1183351A1 Phospholipid transfer protein |
| 03/06/2002 | EP1183243A1 Short-acting benzodiazepines |
| 03/06/2002 | EP1183233A2 Bradykinin receptor antagonists |
| 03/06/2002 | EP1183049A2 Modification of biological elements |
| 03/06/2002 | EP1183040A1 Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway |
| 03/06/2002 | EP1183039A1 Pharmaceutical preparations of bioactive substances extracted from natural sources |
| 03/06/2002 | EP1183037A2 Methods and compositions for modulating immune response and for the treatment of inflammatory disease |
| 03/06/2002 | EP1183019A2 Ace-2 inhibiting compounds and methods of use thereof |
| 03/06/2002 | CN1338958A The use of 4-H-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation |
| 03/06/2002 | CN1338934A Mono-acyloxy aralkyl neuronuscular relaxants |
| 03/06/2002 | CN1338929A Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders |
| 03/06/2002 | CN1338923A Method for controlling liposome size |
| 03/06/2002 | CN1080122C Medicine for injury pain and its preparation |
| 03/05/2002 | US6352995 Spiro-quinuclidine derivatives, their preparation and use |
| 03/05/2002 | US6352971 Polypeptides with amino acid sequences |
| 03/05/2002 | CA2266565C Azabicyclic rotomase inhibitors |
| 02/28/2002 | WO2002016434A1 T CELL RECEPTOR Vβ-Dβ-Jβ SEQUENCE AND METHODS FOR ITS DETECTION |
| 02/28/2002 | WO2002016395A1 Prodrugs of betulinic acid derivatives for the treatment of cancer and hiv |
| 02/28/2002 | WO2002016394A1 Thioether-sulphamate steroids as steroid sulphatase inhibitors and anti-cancer compounds |
| 02/28/2002 | WO2002016393A1 17-aryl-linker derivatised estrogen 3-sulphamates as inhibitors of steroid sulphatase |
| 02/28/2002 | WO2002016392A1 Oestrogen-17-sulphamates as inhibitors of steroid sulphatase |
| 02/28/2002 | WO2002016370A1 1h-imidazopyridine derivatives |
| 02/28/2002 | WO2002015917A1 Use of agaricus blazei murill to prevent or treat skin and other disorders |
| 02/28/2002 | WO2001085779A3 Protein complexes and assays for screening anti-cancer agents |
| 02/28/2002 | WO2001085762A3 Cancer diagnosis and assays for screening anti-cancer agents |
| 02/28/2002 | WO2001081343A3 Compounds for treating fibromyalgia and chronic fatigue syndrome |
| 02/28/2002 | WO2001079271A9 Albumin fusion proteins |
| 02/28/2002 | WO2001079258A9 Albumin fusion proteins |
| 02/28/2002 | WO2001076530A3 Il-8 receptor antagonists |
| 02/28/2002 | WO2001064639A3 Pde iv inhibiting amides, compositions and pharmaceutical use |
| 02/28/2002 | WO2001049309A3 Combinations of growth factors and i: upa or i: mmp for the treatment of damaged tissue |
| 02/28/2002 | WO2001045714A3 Formulations of adenosine a1 agonists |
| 02/28/2002 | WO2001042216A3 Caspase inhibitors and uses thereof |
| 02/28/2002 | WO2001027254A3 Gene transfer vectors for treating autoimmune diseases and diseases with immunopathogenesis by therapy |
| 02/28/2002 | WO2001001970A3 New uses potassium channel openers, such as the treatment of epilepsy |
| 02/28/2002 | US20020026056 Substituted imidazoles having cytokine inhibitory activity |
| 02/28/2002 | US20020025966 Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments |
| 02/28/2002 | CA2420283A1 T cell receptor v.beta.-d.beta.-j.beta. sequence and methods for its detection |
| 02/27/2002 | EP1181385A2 Modulation of gene expression in gastrointestinal inflammation |
| 02/27/2002 | EP1181367A2 Polynucleotides and membrane-bound polypeptides encoded thereby |
| 02/27/2002 | EP1181317A1 An integrin heterodimer and an alpha subunit thereof |
| 02/27/2002 | EP1181282A2 Benzothiazinone and benzoxazinone compounds |
| 02/27/2002 | EP1181054A1 A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders |
| 02/27/2002 | EP1181010A1 Pharmaceutical chewing gum formulations |
| 02/27/2002 | CN1337877A Method of preparing stable suspension of insoluble microparticles |
| 02/21/2002 | WO2002014536A2 Odulating multiple lineage kinase proteins |
| 02/21/2002 | WO2002014487A2 Adeno-associated virus-mediated delivery of angiogenic factors |
| 02/21/2002 | WO2002014281A1 Pyridine derivatives as inhibitors of p38 |
| 02/21/2002 | WO2002013861A2 Method and composition for altering a t cell mediated pathology |
| 02/21/2002 | WO2002013758A2 System for regulating in vivo the expression of a transgene by conditional inhibition |
| 02/21/2002 | WO2001090063A3 Prodrug of an ice inhibitor |
| 02/21/2002 | WO2001085256A3 Critical illness neuropathy |
| 02/21/2002 | WO2001079443A3 Albumin fusion proteins |
| 02/21/2002 | WO2001078533A3 Nutritional modules |
| 02/21/2002 | WO2001072977A3 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| 02/21/2002 | WO2001072960A3 Il-8 receptor antagonists |
| 02/21/2002 | WO2001070807A3 G-protein associated molecules |
| 02/21/2002 | WO2001066089A3 Pharmaceutical compositions comprising cannabis |
| 02/21/2002 | WO2001057069A3 Targeting peptides |
| 02/21/2002 | WO2001049703A3 Substituted sapogenins and their use |
| 02/21/2002 | WO2001043775A3 Hydroxide-releasing agents as skin permeation enhancers |
| 02/21/2002 | WO2001030300A3 Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies |
| 02/21/2002 | WO2000066148A9 Novel proteins |
| 02/21/2002 | WO2000054729A8 Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| 02/21/2002 | US20020022648 Novel 2H-tetrazole-amide compounds with therapeutic activity as metabotropic glutamate receptor agonists |
| 02/21/2002 | US20020022645 Administering benzofuran derivative for therapy of disease state that is capable of being modulated by inhibition of phosphodiesterase IV or Tumour Necrosis Factor |
| 02/21/2002 | US20020022637 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
| 02/21/2002 | US20020022236 Accurately measuring albumin in urine sample; obtain urine, detect presence of adjusted and wildtype albumin in sample |
| 02/21/2002 | CA2419985A1 Modulating multiple lineage kinase proteins |
| 02/21/2002 | CA2419790A1 System for regulating in vivo the expression of a transgene by conditional inhibition |
| 02/21/2002 | CA2419245A1 Adeno-associated virus-mediated delivery of angiogenic factors |
| 02/21/2002 | CA2418389A1 Pyridine derivatives as inhibitors of p38 |
| 02/21/2002 | CA2416794A1 Method and composition for altering a t cell mediated pathology |
| 02/20/2002 | EP1180524A1 Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides |
| 02/20/2002 | EP1180144A2 Cytoskeleton-associated proteins |
| 02/20/2002 | EP1180101A1 Compounds having cytokine inhibitory activity |
| 02/20/2002 | EP1180037A2 Therapeutic uses of agents that modulate the activity of alpha-smooth muscle actin |
| 02/20/2002 | CN1336930A Bridged heterocyclic derivatives |
| 02/20/2002 | CN1336917A Amide compounds |
| 02/14/2002 | WO2002012501A2 Anti-dual integrin antibodies, compositions, methods and uses |
| 02/14/2002 | WO2002012346A2 A new slit-like protein obtained from a cdna library from hs-5 stromal cell line |
| 02/14/2002 | WO2002012340A2 Transporters and ion channels |
| 02/14/2002 | WO2002012286A2 Stress proteins and peptides and methods of use thereof |
| 02/14/2002 | WO2002012258A1 New immunoeffector compounds |
| 02/14/2002 | WO2002012244A2 Polymorphs of zaleplon and methods for the preparation thereof |
| 02/14/2002 | WO2002012239A1 Benzimidazole derivatives, preparation and therapeutic use thereof |
| 02/14/2002 | WO2002012192A1 Quinolene derivatives as anti-inflammation agents |
| 02/14/2002 | WO2002011724A2 Neuroprotective 2-pyridinamine compositions and related methods |
| 02/14/2002 | WO2001081415A9 Parathyroid hormone and parathyroid hormone-related protein antagonists |
| 02/14/2002 | WO2001068670A3 Family of mechanically sensitive human potassium channels activated by polyunsaturated fatty acids and use thereof |
| 02/14/2002 | WO2001042288A3 G-protein coupled receptors |
| 02/14/2002 | WO2001037852A3 Methods of inhibiting atrophy or promoting hypertrophy |
| 02/14/2002 | WO2000061188A9 Sodium channel blocker compositions and the use thereof |
| 02/14/2002 | US20020019563 A S-(2-(1-iminoethyl)amino)ethyl)-2-methyl-L-cysteine |
| 02/14/2002 | US20020019531 Indoles |